Answer
Sep 18, 2024 - 12:47 PM
Entresto (sacubitril/valsartan) is generally considered effective for treating heart failure with reduced ejection fraction, but it does come with potential risks such as hypotension, hyperkalemia, and renal impairment. While not universally categorized as "high risk," it requires careful monitoring and management to mitigate these risks, especially in patients with existing health conditions.
